Zacks Investment Research Downgrades INDIVIOR PLC/S (INVVY) to Sell
INDIVIOR PLC/S (OTCMKTS:INVVY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “
INVVY has been the subject of a number of other reports. ValuEngine cut INDIVIOR PLC/S from a “hold” rating to a “sell” rating in a report on Wednesday, July 11th. Citigroup reissued a “neutral” rating on shares of INDIVIOR PLC/S in a report on Thursday, May 31st.
INDIVIOR PLC/S (OTCMKTS:INVVY) last released its quarterly earnings results on Thursday, July 26th. The company reported $0.45 earnings per share (EPS) for the quarter. The business had revenue of $268.00 million during the quarter. research analysts predict that INDIVIOR PLC/S will post 1.74 EPS for the current fiscal year.
About INDIVIOR PLC/S
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, overdose rescue, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.
Recommended Story: Book Value Per Share in Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for INDIVIOR PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INDIVIOR PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.